The BCG vaccine: information and recommendations for use in Australia
DOI:
https://doi.org/10.33321/cdi.2006.30.5Keywords:
BCG vaccine, guidelines, recommendations, Bacille Calmette-GuérinAbstract
The Bacille Calmette-Guérin (BCG) vaccine since its first use in 1921 has been the subject of much controversy as to its effectiveness and applicability. BCG vaccination is still considered an important strategy in the National Tuberculosis Programs of countries with a high burden of tuberculosis (TB) because of its benefit to infants but its effect on the control of TB has been limited. By contrast, in countries with a low prevalence of TB, significant policy differences exist both within and between countries.
BCG vaccination does not prevent transmission of infection to the individual. In immune-competent neonates and infants it is accepted that BCG reduces the likelihood of TB infection progressing to disease or if disease occurs, substantially lessens the chance of a severe outcome. The benefit in older age groups is less clear.
In the Australian health worker, the BCG strategy is no longer recommended as the primary means of health care worker (HCW) protection. The preferred strategy is appropriate infection control measures, staff education and a tuberculin skin testing program that identifies and treats the at-risk infected HCW. The emergence of multi-drug resistant strains has however renewed interest in BCG in the HCW.
This document provides recommendations for use of the BCG vaccine in the Australian community based on the best available evidence and consensus opinion. State and Territory TB Control Units should be consulted with regard to their BCG vaccination guidelines.
Downloads
References
Executive Committee and Council of IUATLD. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guérin (BCG) in countries with a low prevalence of tuberculosis. IUATLD Newsletter, May 1994.
Styblo, K. Epidemiology of Tuberculosis. Selected Papers, 24. Royal Netherlands Tuberculosis Association, 1991.
Romanus V, Svensson A, Hallander HO. The impact of changing BCG coverage on tuberculosis incidence in Swedish born children between 1969 and 1989. Tuber Lung Dis 1992;73,150–161.
Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983;249:2362–2369.
Smith PG. Case-control studies of the efficacy of BCG against tuberculosis. In: International Union Against Tuberculosis, ed. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services International, 1987;73–79.
Tripathy SP. Fifteen-year follow-up of the Indian BCG prevention trial. In: International Union Against Tuberculosis, ed. Proceedings of the XXVIth IUAT World Conference on Tuberculosis and Respiratory Diseases. Singapore: Professional Postgraduate Services International, 1987;69–72.
The role of BCG vaccine in the prevention and control of tuberculosis in the United States . A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996;45(RR–4):1–18.
Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988;44:691–703.
Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698–702.
Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993;22:1154–1158.
Stevens JP, Daniel TM. Bacille Calmette-Guérin immunization of health care workers exposed to multidrug-resistant tuberculosis: a decision analysis. Tuber Lung Dis 1996;77:315–321.
Marcus AM, Rose DN, Sacks HS, Schechter CB. BCG vaccination to prevent tuberculosis in health care workers: a decision analysis. Prev Med 1997;26:201–207.
Greenberg PD, Lax KG, Schechter CB. Tuberculosis in house staff. A decision analysis comparing the tuberculin screening strategy with the BCG vaccination. Am Rev Respir Dis 1991;143:490–495.
Stapledon RA, Lumb R, Lim IS. Chemoprophylaxis and BCG in contacts of multidrug resistant tuberculosis. Chapter 14, 213–224. In: Bastian I, Portaels F, eds. Multidrug-resistant tuberculosis. Kluwer Academic Publishers. The Netherlands 2000.
Management of persons exposed to multidrug-resistant tuberculosis. MMWR Recomm Rep 1992;41(RR–11):61–71.
Report of the Public Health Committee NHMRC. Towards Elimination of Tuberculosis. A strategic framework for tuberculosis control in Australia, 1993.
Miller M, Lin M, Spencer J, Antic R, Bastian I, Christensen A, et al. Tuberculosis notifications in Australia, 2001. Commun Dis Intell 2002;26:525–536.
Samaan G, Roche P, Spencer J, Bastian I, Christensen A, Hurwitz M, et al. Tuberculosis notifications in Australia, 2002. Commun Dis Intell 2003;27:448–458.
Li J, Roche P, Spencer J, Bastian I, Christensen A, Hurwitz M, et al. Tuberculosis notifications in Australia, 2003. Commun Dis Intell 2004;28:464–473.
Krause VL. Tuberculosis in the young: focusing on those at risk. Med J Aust 1998;168:100–101.
Beilby J, Reed J, Baker J, Wilson K, Sansbury M, Antic R, et al. Tuberculosis surveillance in the South Australian Aboriginal community. Med J Aust 1990;153:149–155.
Plant AJ, Krause VL, Condon JR, Kerr C. Aborigines and tuberculosis: why they are at risk. Aust J Public Health 1995;19:487–491
Johnson PD, Carlin JB, Bennett CM, Phelan PD, Starr M, Hulls J, et al. Prevalence of tuberculosis infection in Melbourne secondary school students. Med J Aust 1998;168:106–110.
Alperstein G, Morgan KR, Fett MJ, Nossar V, Stewart GJ. Prevalence of tuberculosis infection among primary school-entry children in Sydney . Aust N Z J Public Health 1996;20:123–128.
Markey P, Barclay L, Krause V. NT Mantoux school screening 1991–2000. Northern Territory Disease Control Bulletin 2002;9:6–9.
Broomell K, Antic R, Stapledon R. A decade of tuberculosis control in SA. Abst. Program and Abstracts. The 2nd National Tuberculosis Conference: Australia 's regional role in tuberculosis control. 1997 Nov 17–18:38. Sydney: The Public Health Association of Australia, 1997.
Lotte A, Wasz-Hockert O, Poisson N, Engbaek H, Landmann H, Quast U, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988;63:47–59.
Lotte A, Wasz-Hockett O, Poisson N, Dumitrescu N, Verron M. Complications induced by BCG vaccination; retrospective study. Bull Int Union Tuberc 1980;55:58–67.
Turnbull FM, McIntyre PB, Achat HM, Wang H, Stapledon R, Gold M, et al. National study of adverse reactions after vaccination with Bacille Calmette-Guérin. Clin Infect Dis 2002;34:447–453.
Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tuber Lung Dis 1992;73:252–261.
Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17–24.
Tala-Heikkila MM, Tuominen JE, Tala EO. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998;157:1324–1327.
Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005;366:1290–1295.
Global tuberculosis programme and global programme on vaccines: Statement on BCG revaccination for the prevention of tuberculosis. Wkly Epidemiol Rec 1995;70:229–231
Griffin JF, Chinn DN, Rodgers CR, Mackintosh CG. Optimal models to evaluate the protective efficacy of tuberculosis vaccines. Tuberculosis (Edinb) 2001;81:133–139.
Orme IM. Progress in the development of new vaccines against tuberculosis. Int J Tuberc Lung Dis 1997;1:95–100.
Doherty TM, Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 2005;18:687–702.
Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998;2:200–207.
Downloads
Published
How to Cite
License
Copyright (c) 2006 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
